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Abstract
Background: The aim of the present study was to verify whether BNP might detect pre-clinical diastolic
dysfunction (LVDD) in type-2 diabetic patients.
Methods: One-hundred and twenty-seven consecutive outpatients with type-2 diabetes mellitus were enrolled
into the study. Subjects with overt heart failure or NYHA class > 1, history of coronary artery disease, severe
valvulopathy or chronic atrial fibrillation were excluded from the study. All patients underwent clinical evaluation,
laboratory assessment of brain natriuretic peptide (BNP) and echocardiographic examination.
Results: No patients showed systolic impairment of left ventricular function, whereas diastolic dysfunction was
detected in 53 (42%) cases (all impaired relaxation). Median BNP was 27 pg/ml without any significant difference
between 76 patients with normal left ventricular function and 53 with diastolic dysfunction; in 54 (43%) patients
showing HBA1C≥8 (uncontrolled diabetes) normal function was found in 32 and diastolic dysfunction in 22, with a
significant difference of BNP at multivariate analysis (OR = 1.02, 95%CI = 1.05-1.09, p = 0.003). In uncontrolled
diabetic cohort, BNP was a strong predictor for LVDD (OR = 2.7, 95%CI = 1.3-5.6, p = 0.006) along with the
duration of diabetes (OR = 1.6, 95%CI = 1.1-2.9, p = 0.046). BNP > 25 pg/ml was a cut-off value with high accuracy
to detect a LVDD.
Discussion: Early screening of high-risk patients for diabetic cardiomyopathy development might be useful to
better control glycemic profile in order to reduce heart disease progression or even to reverse it
Conclusions: BNP could be a cheap, easy and useful tool to screen those ones with preclinical ventricular diastolic
dysfunction in a subset of patients particularly prone to develop cardiovascular complications, like uncontrolled
diabetic patients.
Background
Diabetes mellitus (DM) is not only a significant inde-
pendent risk factor for developing of atherosclerotic
ischemic heart disease or ventricular hypertrophy but it
is also able to trigger a diabetic cardiomyopathy due to
some dysmetabolic processes: inhibition of switching
within the cardiomyocite from free-fatty acid (FFA) to
glucose metabolism, dysregulation of FFA metabolism
with increased uptake, reduced FFA oxidation, reduction
of peroxisome proliferator-activated receptors (PPAR),
increase of PPAR-g and insulin-resistance, increased
intracellular lipogenesis which leads to cardiomyocite
lipotoxiocity [1].
The patients with type-2 DM are at 2-5 folds higher
risk for developing heart failure (HF) [2]. Some large
trials reported that the prevalence of diabetes in patients
with chronic heart failure is around 30% and close to
50% in those with acute HF [3-5] The first stage of dia-
betic cardiomyopathy is represented by left ventricular
diastolic dysfunction (LVDD) with preserved systolic
function, in an asymptomatic pattern [6-9]; the preva-
lence of diastolic dysfunction largely ranges from 30% to
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used to define it [7,10-13].
Internationally, there is an increased focus on preven-
tion since even pre-clinical diabetic cardiomyopathy can
impair significantly event-free survival [14], thus, in
order to deal with this issue, neurohormonal profile of
diabetic patients could be a good tool to screen subclini-
cal ventricular dysfunction instead of cardiac imaging
technique, which required elevated costs and human
resource expenditure. For this purpose, brain natriuretic
peptide (BNP) was demonstrated to be a good diagnos-
tic and prognostic marker in diabetic patients with heart
failure [15], systolic dysfunction [16], silent myocardial
ischemia [17] and vascular complications [18]. The diag-
nostic role of natriuretic peptides for detecting LVDD in
asymptomatic diabetic patients is still debated
[14,17,19-21].
Hence, the aim of the present study is to verify
whether BNP might detect pre-clinical diastolic dysfunc-
tion in type-2 diabetic patients.
Methods
Study population
One hundred and twenty-seven consecutive outpatients
(age range 35-65 years, mean ± SD 55 ± 7 years), with
type-2 diabetes mellitus according to ADA/WHO cri-
teria [22] were enrolled into the study. Subjects with
overt heart failure or NYHA class > 1, history of coron-
ary artery disease, severe valvulopathy or chronic atrial
fibrillation were excluded from the study.
All patients underwent clinical evaluation, laboratory
assessment of BNP and echocardiographic examination
(Table 1). Concerning antidiabetes therapy, 9% of them
were on insulin treatment, 60% took oral antidiabetes
agents and 6% had both treatments; the remaining 31%
of patients were on diet. Other therapies were ACE-
inhibitors (22%), ARB (9%), b-blockers (10%), calcium-
channel blockers (6%), a-blockers (4%) and diuretics
(12%).
All patients gave their written informed consent; the
investigation conforms to the principles outlined in the
Declaration of Helsinki and the study was approved by
the local ethics committee (The University of L’Aquila).
Laboratory
Blood samples were taken after 5 minutes of supine rest.
BNP was measured using the commercially available
AxSYM BNP assay, produced by Axis-Shield and Abbott
Laboratories. Glycated hemoglobin (HBA1C) were mea-
sured using Menarini HA8140 assay. Microlabuminuria
was defined as extemporary albuminuria value equal or
greater than 20 mg/L.
Echocardiography
M-mode, two-dimensional images and pulsed-wave and
color-flow-Doppler examinations were performed on the
same day of BNP assays, with a commercially available
imaging system (ESAOTE MyLAB 30). Left ventricular
systolic and diastolic volumes and ejection fraction (EF)
were derived from the biplane apical modified Simpson’s
rule algorithm. Left ventricular dimensions were mea-
s u r e df r o mM - m o d ei m a g e saccording to standard cri-
teria. Diastolic dysfunction was assessed by means of
transmitral pulsed-wave Doppler velocity (E/A ratio),
deceleration time. In addition, pulmonary venous systo-
lic and diastolic flow velocities were obtained as the
Table 1 Demographic, clinical and echocardiographic characteristics
POPULATION OVERALL
n = 127
Group A
N=7 4
Group B
N=5 3
p-value
Age (years) 55.2 ± 6.8 54.5 ± 6.8 56.3 ± 6.8 0.155
Gender (M/F) 65/62 38/36 24/29 0.500
BMI (Kg/m2) 29.2 ± 5.0 29.1 ± 5.1 29.5 ± 5.2 0.867
Diabetes duration (years)* 3 (1-10)* 3 (1-10)* 3 (1-9) 0.954
Smokers 28 (22%) 14 (19%) 14 (26%) 0.577
Ex-smokers 40 (31%) 25 (34%) 15 (28%) 0.504
Hypertension 51 (40%) 27 (37%) 24 (45%) 0.361
Hypercholesterolemia 29 (23%) 19 (26%) 10 (19%) 0.447
Creatinine (mg/dl) 0.89 ± 0.21 0.87 ± 0.21 0.94 ± 0.21 0.115
Microalbuminuria 34 (29%) 18 (28%) 16 (31%) 0.666
LVEF (%) 59.4 ± 4.8 60.5 ± 5.5 58.8 ± 3.7 0.143
LVMI (g/m2.7) 43.7 ± 11.8 42.6 ± 12.1 45.2 ± 11.3 0.198
LVH 51 (40%) 27 (36%) 24 (45%) 0.361
LVEF = left ventricular ejection fraction, LVMI = left ventricular mass index, LVH = left ventricular hypertrophy.
*data are expressed as median and interquartile range.
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Page 2 of 7maximal value reached during the corresponding phase
of each cardiac cycle. Diastolic dysfunction was classified
into 3 categories as follows: impaired relaxation, pseudo-
normal filling pattern and restrictive-like filling pattern, as
previous reported [23]. Left ventricular mass (LVM) was
calculated according to the following formula: 0.8 × [1.04
(IVS + LVDD + PWT)
3 -L V D D
3] + 0.6 g [24]. All echo-
cardiographic data were indexed by height to the
allometric power of 2.7 [25] Left ventricular hypertrophy
was defined as an LVM ≥ 50 g/m
2.7 in men and ≥ 47 g/m
2.7
in women.
A single observer (LG) made all measurements. Using
digital archiving images, intraobserver variability was
tested in a blinded fashion. Intraobserver variability was
3.3%, 3.9%, 5.1%, 8.5% and 9.2% for E/A ratio, E wave
deceleration time, pulmonary venous systolic and diasto-
lic flow velocities, EF and calculated left ventricular
mass index (LVMI), respectively.
End-points
The aim of this study was to evaluate the diagnostic role
of BNP assays in early identification of diastolic dysfunc-
tion in diabetic patients, asymptomatic for heart failure.
Particularly, since that an uncontrolled diabetes is
strongly related to development of left ventricular dys-
function and chronic heart failure [21], a further analysis
has been performed in this particular subset of patients.
To define uncontrolled diabetes, an average of last two
years HBA1C values were used; HBA1C equal or higher
of 8% was chosen as threshold for uncontrolled diabetes,
more prone to develop heart and vascular complications
[26].
Statistics
Results were expressed as mean (± standard deviation)
for normally distributed continuous variables, whereas
non-normally distributed data were expressed as median
and interquartile range (IQR): 25
th and 75
th percentile;
Categorical variables were reported as count and per-
centage. Distribution of continuous variables was tested
for normal distribution using the Kolmogorov-Smirnov
test. Paired-comparison was performed by means of
Wilcoxon test whereas unpaired-comparison was per-
formed by means of t-test or Mann-Whitney U test.
Categorical data were compared by X2-test or Fisher
exact test where appropriate. Logistic regression was
used to identify predictive factors for LVDD. The vari-
ables initially inserted into the regression model were:
age, gender, body mass index, systolic blood pressure,
diastolic blood pressure, diabetes duration (years) smo-
kers/ex-smokers, hypertension, hypercholesterolemia,
obesity (BMI > 30 Kg/m2), left ventricular mass index
(g/m2.7), last 2-year average HBA1C (%), creatinine
(mg/dl), microalbuminuria, type of antidiabetic therapy,
type of anti-hypertensive medication, BNP, hypertension
plus left ventricular hypertrophy (duration of diabetes
and BNP were non-normally distributed and so they
underwent log-transformation before being inserted into
the initially model). Variables included in the final
model were reported as odd ratio (OR), 95% confidence
interval (CI) and p-value.
Receiver operating characteristic (ROC) curve analysis
was used to identify predictive cut-offs. Each statistical
analysis was validated in 1000 bootstrap samples. A
probability value p < 0.05 was considered significant.
The retrospective power calculation, using as target
end-point the comparison of BNP levels between uncon-
trolled diabetic patients with versus without diastolic
dysfunction, estimates that 18 cases were the minimum
sample size per each group to achieve a power of 80%
with an a-error of 0.05.
All analyses were performed with the statistical soft-
ware package SPSS (SPSS Inc, Chicago, IL, US).
Results
No patients showed systolic impairment of left ventricu-
lar function, whereas diastolic dysfunction was detected
in 53 (42%) cases; all of them were classified as impaired
relaxation pattern; all the remaining 74 cases showed
normal diastolic function. All the population had a crea-
tinine equal or below 1.5 mg/dl; microalbuminuria was
present in 29% of cases without any difference between
patients with and without ILDD (Table 1)
Overall BNP median value was 27 pg/ml (IQR = 6-55)
without any significant difference between 76 patients
with normal left ventricular function (Group A) and those
ones with diastolic dysfunction (Group B) (Figure 1). The
Figure 1 Box-plots: BNP value according to absence or
presence of diastolic dysfunction. Numeric data reported in the
figure are median and interquartile range.
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model was the contemporary presence of hypertension
and left ventricular hypertrophy (OR = 2.6, 95%CI = 1.1-
6.5, p = 0.044).
Last two-year average HBA1C value was 7.7 ± 1.8
without any difference between the two groups (diastolic
dysfunction 7.7 ± 1.8 vs normal function 7.7 ± 1.9, p =
0.905); Fifty-four (43%) out of 127 patients showed
HBA1C≥8 (uncontrolled diabetes) with a mean value of
9.3 ± 1.7. The remaining group of patients (73) showed
a mean HBA1C of 6.5 ± 0.6 (p vs uncontrolled diabetes
< 0.001). In 73 patients with well-controlled diabetes,
BNP level was not predictive for diastolic dysfunction
(p = 0.244), whereas BNP seems to be a good predictive
in the uncontrolled-diabetes cohort
The uncontrolled diabetes group was split into 2
groups: normal function (Group A, n = 32) and diastolic
dysfunction (Group B, n = 22). The two groups did not
show any difference concerning demographic, clinical,
echocardiographic data (table 2).
The value of BNP was significantly higher in group B
than in group A (Figure 2); the binary logistic regression
confirmed that BNP was related to higher prevalence of
LVDD (Log-transformation: OR = 2.7, 95%CI = 1.3-5.6,
p = 0.006) along with the duration of diabetes (Log-
transformation: OR = 1.6, 95%CI = 1.1-2.9, p = 0.046).
Moreover, BNP was a strong predictor for LVDD in
uncontrolled diabetes cohort (AUC = 0.80, 95%CI 0.66-
0.89, p < 0.001) with a cut-off value of 25 pg/ml above
that the likelihood to show a DD is high (sensitivity =
7 7 %a n ds p e c i f i c i t y=7 8 % )( F i g u r e3 ) ;t h er a t eo f
patients having BNP > 25 pg/ml was significantly higher
in group B (77% vs 22%, p < 0.001).
Discussion
Prevalence of subclinical isolated diastolic dysfunction in
type-2 diabetic population
Our data show a prevalence of asymptomatic diastolic
dysfunction of roughly 42%, perfectly included within
the range, from 30% to 63%, reported by those studies
where LVDD was assessed by means of conventional
echocardiography [7,10-13,27,28]. In our series, the pre-
sence of LVDD was independent by age and gender
unlike reported by other Authors which clearly found a
relationship between these factors and the prevalence of
LVDD in diabetic patients [7,10,11]. Anyway, the pre-
sence of hypertension along with left ventricular hyper-
trophy increased the prevalence of LVDD up to 61%
(14/23) versus 38% (39/104), p = 0.040; this result was
confirmed also by binary logistic regression (OR = 2.6,
95%CI = 1.1-6.5, p = 0.044), corroborating that combi-
nation of DM and HTN has more severe impact on ven-
tricular filling pattern [27].
However, the diastolic function was impaired also in
38% of 104 diabetic patients without HTN+LVH, similar
either in presence of HTN or not (p = 0.819). To
explain the patho-physiological basis of this left ventri-
cular impaired relaxation, the concept that diabetes per
se might cause a stand-alone cardiomyopathy should be
accepted [1]. Diabetic cardiomyopathy has been defined
Table 2 Difference between patient without and with
diastolic dysfunction, in uncontrolled diabetic cohort
(HBA1C≥8%)
POPULATION Group A
n=3 2
Group B
n=2 2
p-value
Age (years) 52.6 ± 6.8 54.5 ± 8.4 0.355
Gender (M/F) 17/15 9/13 0.377
BMI (Kg/m2) 29.5 ± 5.1 30.2 ± 5.7 0.691
Diabetes duration (years)* 4 (0.7-10) 7 (3-10) 0.225
Smokers 6 (19%) 8 (36%) 0.303
Ex-smokers 8 (25%) 5 (23%) 0.848
Hypertension 7 (22%) 8 (36%) 0.243
Hypercholesterolemia 8 (25%) 5 (23%) 0.848
Creatinine (mg/dl) 0.90 ± 0.22 0.95 ± 0.24 0.407
Microalbuminuria 33 (33%) 30 (30%) 1.000
LVEF (%) 58.8 ± 5.2 58.9 ± 3.4 0.922
LVMI (g/m2.7) 38.7 ± 9.8 40.9 ± 11.4 0.461
LVH 4 (13%) 6 (27%) 0.170
HBA1C 9.3 ± 1.6 9.4 ± 1.8 0.707
Insulin 7 (22%) 4 (18%) 0.741
Oral antidiabetic agents 18 (56%) 15 (68%) 0.377
LVEF = left ventricular ejection fraction, LVMI = left ventricular mass index,
LVH = left ventricular hypertrophy.
*data are expressed as median and interquartile range.
Figure 2 Box-plots: BNP value according to absence or
presence of diastolic dysfunction, in uncontrolled diabetic
cohort. Numeric data reported in the figure are median and
interquartile range.
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absence of coronary artery disease, hypertension or
other significant etiology [29] In a very recent report,
Anderson and coworkers [30] compared two cohorts of
31 patients having EF > 35%, without significant coron-
a r ya r t e r yd i s e a s e( C A D ) ,p r ior myocardial infarction,
cardiac pacemaker, atrial fibrillation, or significant valve
disease, one diabetic and the other one controls, match-
ing the two groups on age, gender and presence of
hypertension. The Authors concluded that In this set of
patients diabetes is anyway associated with global diasto-
lic dysfunction. This finding is in accordance with the
hypotheses of increased myocardial stiffness, increased
resting myocyte tension and deposition of advanced gly-
cated end products associated with diabetic cardiomyo-
pathy; In fact, intracellular hyperglycemia is at basis of
formation of advanced-glycated end products (AGEs) as
collagen, elastin and other connective tissue proteins
[31] which produce myocardial fibrosis resulting in dia-
stolic dysfunction.
BNP and diastolic dysfunction
T h ed i a g n o s t i cr o l ep l a y e db yB N Pi ne a r l yd e t e c t i o no f
asymptomatic diastolic dysfunction in type-2 diabetes is
still controversial [14,16,19-21,32-34]. In our, series, we
failed to identify any difference between patients with
normal function and those ones with LVDD regarding
BNP value (Figure 1). The possible explanation of this
results can be the presence of just impaired relaxation
in our population which represents the mild grade of
LVDD [19,20]. In fact, Magnusson et al, [19] described a
detecting role of BNP with respect to LVDD, but only in
case of moderate-to-severe LVDD; comparing patients
with and without mild LVDD the Authors did not find
any difference (lnBNP 1.3 ± 0.8 vs 0.98 ± 0.85, p = 0.09)
and this finding was confirmed also at multivariate ana-
lysis. Conversely, comparing patients with moderate-to-
severe LVDD, lnBNP was significantly higher (2.1 ± 1.4
vs 0.98 ± 0.85, ‘ < 0.0001). Kiencke and co-workers [14]
analyzed 100 adults with diabetes in order to evaluate if
BNP could predict pre-clinical diastolic dysfunction in
diabetic cardiomyopathy. They concluded that BNP had
higher prognostic than diagnostic role. Although the
ROC curve analysis identified BNP as predictor for dia-
stolic dysfunction, the area under curve (0.70) showed a
low accuracy of BNP test and the identified cut-off
value of 34 pg/dl showed a moderate sensitivity (66%)
and specificity (71%). The suggestion that BNP is very
likely unable for early detection of LVDD was confirmed
by others [20].
On the contrary, Albertini and co-workers [16] assessed
BNP value in 91 consecutive patients with type 2 diabetes
mellitus, finding that BNP level was significantly higher in
patients with LVDD, especially in case of untreated
hypertension (87 ± 20 vs 13 ± 2, p < 0.0001); anyway,
comparing the mean value of patient with normal LV
function with those ones with LVDD, independently
from the anti-hypertensive treatment, BNP was signifi-
cantly higher in the latter group (p < 0.001). In another
report, the area under the receiver-operating characteris-
tic curve for NT-proBNP to separate normal versus dia-
stolic dysfunction, in type 2 diabetic patients, was even
0.96 [32]. Kim et al [33] assessed NT-proBNP levels in a
group consisted of 130 diabetic patients referred for
echocardiography, finding that in diastolic dysfunction
were significantly higher than normal group (1491.1 pg/
mL versus 232.3 pg/mL, P = 0.01), even though there
was no difference in ejection fraction (EF) (61.2+/-7.9%
versus 60+/-8.4%, P = 0.773).
BNP and diastolic dysfunction in uncontrolled diabetic
subset
Also Dencker et al [21] demonstrated that BNP was sig-
nificantly higher in patients with abnormal diastolic dys-
function (26.0 ± 3.4 vs 5.3 ± 3.4, p < 0.001) but in a
cohort of 33 patients with poorly regulated type 2 dia-
betes. The authors defined “poorly regulated” when
HBA1C > 7%. In 2001, Menzin J et al [26] found that
HBA1C <8% had roughly 60% fewer hospital admissions
for complications, especially heart complications. Thus,
we decided to perform a sub-analysis in 54 patients with
uncontrolled diabetes (HBA1C≥8%), in order to verify if
BNP might be a good tool for early detection of LVDD
at least in this subset of patients. Both univariate and
multivariate analysis confirmed that higher levels of
BNP were associated with LVDD and ROC curve analy-
sis demonstrated the good accuracy of this parameter
for detecting LVDD; furthermore, a cut-off value was
also identified BNP> 25 pg/ml, with a good sensitivity
Figure 3 ROC curve: BNP is a good predictor for DD in out of
control cohort.
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consistent with the one reported by Albertini et al [16].
Conversely, in 73 patients with well-controlled diabetes,
BNP level was not predictive for diastolic dysfunction.
Limitations of the study
The main limitation of this study is the small sample
size. Another important limits is related to the echocar-
diographic assessment of diastolic dysfunction, that,
nowadays, is more and more evaluated by means of tis-
sue Doppler imaging (TDI).
Clinical implications and Conclusion
There is an important concept raising up from the pre-
sent study, BNP is a good marker for detecting pre-
clinical LVDD in a subset of patients particularly prone
to develop cardiovascular complications, like those ones
with uncontrolled diabetes. In clinical practice it is very
difficult to submit all asymptomatic diabetic subjects to
echocardiographic lab; so BNP could be a cheap, easy
and useful tool to screen those ones with preclinical
ventricular diastolic dysfunction among patients with
high HBA1C. Furthermore, BNP could be use for serial
assessment of this specific cohort of patients asympto-
matic for heart failure.
Another clinical implication concerns the possibility to
better control glycemic profile in order to reduce heart
disease progression or even to reverse it, especially in
patients with short duration of diabetes without history
of cardiovascular event [35,36]; In fact, in the early
stages of diabetes, structural modifications seem to be
partially reversible [8]. Finally, early screening of those
patients with subclinical diastolic dysfunction, is useful
to plan a cardiologic therapy to prevent the develop-
ment of diabetic cardiomyopathy.
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